Nanologica AB (publ) (NICA.ST)
SEK 1.71
(-0.58%)
SEK 1.71
(-0.58%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -69.96 Million SEK | -29.63% |
| 2022 | -50.13 Million SEK | -28.45% |
| 2021 | -39.03 Million SEK | -94.14% |
| 2020 | -20.1 Million SEK | -2.53% |
| 2019 | -19.6 Million SEK | 8.03% |
| 2018 | -21.32 Million SEK | -10.46% |
| 2017 | -19.3 Million SEK | 13.05% |
| 2016 | -22.19 Million SEK | -56.96% |
| 2015 | -14.14 Million SEK | 3.99% |
| 2014 | -14.73 Million SEK | -45.39% |
| 2013 | -10.13 Million SEK | -109.4% |
| 2012 | -4.83 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -14.26 Million SEK | 59.93% |
| 2024 Q2 | -10.17 Million SEK | 31.09% |
| 2023 Q1 | -10.71 Million SEK | 14.51% |
| 2023 Q3 | -10.29 Million SEK | 22.69% |
| 2023 Q2 | -13.31 Million SEK | -24.2% |
| 2023 FY | -64.99 Million SEK | -29.63% |
| 2023 Q4 | -35.6 Million SEK | -245.98% |
| 2022 Q3 | -9.61 Million SEK | 22.47% |
| 2022 Q2 | -12.39 Million SEK | 20.49% |
| 2022 FY | -50.13 Million SEK | -28.45% |
| 2022 Q1 | -15.59 Million SEK | -10.52% |
| 2022 Q4 | -12.53 Million SEK | -30.47% |
| 2021 Q1 | -6.76 Million SEK | -151.41% |
| 2021 FY | -39.03 Million SEK | -94.14% |
| 2021 Q2 | -8.09 Million SEK | -19.59% |
| 2021 Q4 | -14.1 Million SEK | -20.4% |
| 2021 Q3 | -11.71 Million SEK | -44.77% |
| 2020 Q1 | -5.82 Million SEK | 3.74% |
| 2020 FY | -20.1 Million SEK | -2.53% |
| 2020 Q4 | -2.69 Million SEK | 60.23% |
| 2020 Q2 | -4.28 Million SEK | 26.38% |
| 2020 Q3 | -6.76 Million SEK | -57.9% |
| 2019 FY | -19.6 Million SEK | 8.03% |
| 2019 Q3 | -4.96 Million SEK | 0.92% |
| 2019 Q2 | -5 Million SEK | -56.43% |
| 2019 Q1 | -3.2 Million SEK | 42.41% |
| 2019 Q4 | -6.04 Million SEK | -21.89% |
| 2018 Q1 | -4.94 Million SEK | -253.58% |
| 2018 Q2 | -5.76 Million SEK | -16.6% |
| 2018 Q3 | -5.04 Million SEK | 12.48% |
| 2018 Q4 | -5.56 Million SEK | -10.17% |
| 2018 FY | -21.32 Million SEK | -10.46% |
| 2017 Q2 | -6.62 Million SEK | 1.61% |
| 2017 FY | -19.3 Million SEK | 13.05% |
| 2017 Q4 | -1.39 Million SEK | 69.29% |
| 2017 Q3 | -4.55 Million SEK | 31.19% |
| 2017 Q1 | -6.72 Million SEK | -68.05% |
| 2016 Q1 | -5.56 Million SEK | -16.36% |
| 2016 FY | -22.19 Million SEK | -56.96% |
| 2016 Q4 | -4 Million SEK | 34.89% |
| 2016 Q3 | -6.14 Million SEK | 5.09% |
| 2016 Q2 | -6.47 Million SEK | -16.4% |
| 2015 Q4 | -4.78 Million SEK | -8.94% |
| 2015 Q1 | -1.42 Million SEK | 69.71% |
| 2015 Q2 | -3.54 Million SEK | -149.61% |
| 2015 FY | -14.14 Million SEK | 3.99% |
| 2015 Q3 | -4.39 Million SEK | -23.79% |
| 2014 Q4 | -4.69 Million SEK | 0.0% |
| 2014 Q2 | -2.53 Million SEK | 0.0% |
| 2014 Q1 | -2.53 Million SEK | 0.0% |
| 2014 FY | -14.73 Million SEK | -45.39% |
| 2014 Q3 | -4.69 Million SEK | -84.91% |
| 2013 FY | -10.13 Million SEK | -109.4% |
| 2012 FY | -4.83 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 71.9% |
| Ziccum AB (publ) | -21.56 Million SEK | -224.504% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -326.578% |
| BioArctic AB (publ) | 252.64 Million SEK | 127.693% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -8179.645% |
| Mendus AB (publ) | -100.65 Million SEK | 30.489% |
| Genovis AB (publ.) | 54.22 Million SEK | 229.026% |
| Intervacc AB (publ) | -93.57 Million SEK | 25.236% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -351.025% |
| Active Biotech AB (publ) | -46.48 Million SEK | -50.51% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 488.489% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -26.248% |
| Aptahem AB (publ) | -10.1 Million SEK | -592.377% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 78.239% |
| Kancera AB (publ) | -65.04 Million SEK | -7.566% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 48.028% |
| Fluicell AB (publ) | -26.87 Million SEK | -160.289% |
| Saniona AB (publ) | -81.06 Million SEK | 13.695% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -465.54% |
| Biovica International AB (publ) | -126.07 Million SEK | 44.506% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -64.599% |
| AcouSort AB (publ) | -17.48 Million SEK | -300.086% |
| Xintela AB (publ) | -57.23 Million SEK | -22.232% |
| Abliva AB (publ) | -96.54 Million SEK | 27.536% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 78.46% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1896.091% |
| OncoZenge AB (publ) | -15.9 Million SEK | -339.964% |
| Amniotics AB (publ) | -29.07 Million SEK | -140.646% |
| 2cureX AB (publ) | -36.36 Million SEK | -92.402% |
| CombiGene AB (publ) | -36.3 Million SEK | -92.708% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -377.889% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 81.799% |
| Camurus AB (publ) | 532.35 Million SEK | 113.142% |
| Corline Biomedical AB | -1.78 Million SEK | -3812.919% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 61.296% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -67.845% |
| I-Tech AB | 24.43 Million SEK | 386.323% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 91.127% |
| Cyxone AB (publ) | -21.66 Million SEK | -222.991% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 33.975% |
| Biosergen AB | -27.26 Million SEK | -156.604% |
| Cantargia AB (publ) | -290.01 Million SEK | 75.876% |
| NextCell Pharma AB | -43.17 Million SEK | -62.056% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 61.296% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -309.229% |
| SynAct Pharma AB | -224.49 Million SEK | 68.836% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -58.373% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -192.069% |
| LIDDS AB (publ) | -40.67 Million SEK | -72.009% |
| Lipum AB (publ) | -37.25 Million SEK | -87.8% |
| BioInvent International AB (publ) | -369.94 Million SEK | 81.088% |
| Alzinova AB (publ) | -16.52 Million SEK | -323.454% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 72.395% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -994.326% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 39.201% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -247.401% |
| Simris Alg AB (publ) | -36.63 Million SEK | -90.973% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 52.266% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 77.462% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 36.921% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -504.902% |